A new $11.7 million Washington University MPN grant will help researchers investigate a question that matters to patients: can targeting inflammation help keep an MPN from getting worse? The award, announced September 29, 2026, comes from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. Stephen T. Oh, MD, PhD, […]
Polycythemia Vera Hematocrit: Is Below 45% Enough?
By David Wallace – Patient perspective | September 25, 2026 The established polycythemia vera hematocrit target is below 45%. That goal lowers the risk of serious blood clots and cardiovascular death. It does not necessarily mean symptom relief. I learned that the hard way. My circulation-related symptoms often started around 42%, well before I hit the […]
Mimrylo Earns NCCN Category 1 Recommendation for PV
By David Wallace – September 23, 2026 Mimrylo (rusfertide) has been added as a Category 1 treatment option for both low- and high-risk polycythemia vera (PV) in the National Comprehensive Cancer Network’s updated guidelines. For patients who need frequent phlebotomies, the update is another reason to ask whether a medicine designed to control hematocrit could […]
FDA Approves BESREMi for Essential Thrombocythemia (ET)
By David Wallace | September 13, 2026 The FDA approved BESREMi for essential thrombocythemia on August 31, 2026, giving adults with ET their first new FDA-approved treatment in nearly 30 years. BESREMi (ropeginterferon alfa-2b-njft) is a long-acting interferon given by injection every two weeks. If hydroxyurea is not controlling your disease or its side effects […]
FDA Approves Mimrylo (Rusfertide) for Polycythemia Vera
By David Wallace – September 1, 2026 The U.S. Food and Drug Administration approved Mimrylo™ (mim-rahy-loh), the brand name for rusfertide, on August 28, 2026, for the treatment of erythrocytosis in adults with polycythemia vera (PV). Erythrocytosis means the body is making too many red blood cells. Mimrylo is the first FDA-approved hepcidin mimetic for […]
SURPASS-ET: Earlier Ropeginterferon Shows 2-Year Benefit
by David Wallace September 1, 2026 Update Big news for the ET community: The FDA has approved BESREMi® for adults with essential thrombocythemia (ET). Stay tuned for our detailed article explaining what this approval could mean for patients. Two-year results from the Phase 3 SURPASS-ET trial suggest that earlier initiation of ropeginterferon alfa-2b may provide […]
Divesiran Cuts Phlebotomy Need in Phase 2 PV Trial
By David Wallace Silence Therapeutics reported that divesiran met the primary endpoint of the randomized Phase 2 SANRECO trial. Among 48 phlebotomy-dependent polycythemia vera patients, 88% of those receiving divesiran maintained hematocrit below 45% without phlebotomy during weeks 18 through 36, compared with 19% on placebo. The difference was statistically significant. What the Phase 2 […]
How I Achieved Complete Molecular Remission From Polycythemia Vera (PV)
by David Wallace, Founder, PV Reporter & MPN Cancer Connection When I was first diagnosed with polycythemia vera, nobody told me that PV remission was even possible. And the only treatment I was given, phlebotomy alone, guaranteed it wouldn’t be. Today, my blood counts are normal, and the molecular markers driving my PV are undetectable. […]
From Questions to Confidence: Piecing Together the Facts About Essential Thrombocythemia
Sponsored Post Being diagnosed with a rare, chronic blood cancer like essential thrombocythemia, or ET, can feel overwhelming and isolating. In the United States, approximately 24 out of every 100,000 people are currently living with ET. Because ET is uncommon, it may be hard to know where to turn for clear, trustworthy information—especially early in […]
One Pill, Once a Day: FDA Approves Jakafi XR
Summary Ruxolitinib, the cornerstone treatment for myelofibrosis, polycythemia vera, and graft-versus-host disease, just got easier to take. On May 1, 2026, the FDA approved Jakafi XR™, a once-daily extended-release tablet formulation of the same proven drug. It will be available at pharmacies as early as May 8. Key Points Same medicine, simpler schedule: Jakafi XR […]